This family of chemokine has been shown to play a major role in developing inflammation and inflammation-driven fibrosis and CCL2 is a well-characterized target in the treatment of fibrosis in NASH patients. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.